top of page
Search
  • mihirkhajanchi

Abbott India Annual Report 2023 Summary

Updated: Oct 1, 2023

  • Abbott India Limited, a subsidiary of Abbott Laboratories, USA, is known for its high-quality trusted medicines. We specialize in various therapeutic areas including Women’s Health, Gastroenterology, Central Nervous System, Metabolics, Multi-Specialty, and Vaccines.

  • Abbott India’s leading products; most of these are at the top ranks (#1 or #2) in their Respective Participated Markets: Arachitol (Vitamin D deficiency) • Cremaffin Plus (Constipation) • Pankreoflat (Indigestion) • Influvac (Prevention of influenza) • Cremaffin (Constipation) • Zolfresh (Insomnia) • Heptral (Liver disease) • Duphaston (Miscarriage and IVF) • Librax (Irritable bowel disease) • Brufen (Analgesics) • Digene (Antacid) • Duvadilan (Preterm labor) • Prothiaden (Pain & depression) • Creon (Pancreatic insufficiency) • Ganaton (Gastrointestinal dysmotility) • Thyronorm (Hypothyroidism) • Duphalac (Constipation) • Vertin (Vertigo) • Colospa (Irritable bowel disease) • Udiliv (Cholestatic chronic liver disease)

  • During FY 2022-23, we introduced 10 new products in various therapeutic areas, Women's Health, Gastroenterology, Metabolic, and Multi-Specialty.

  • Diversified Product Portfolio: We provide a wide variety of products to meet diverse health needs. Our comprehensive portfolio covers multiple therapeutic categories such as Women’s Health, Gastroenterology, Neurology, Thyroid, Pain Management, Vitamins, and Vaccines. 125+ Products in portfolio 10 New products introduced in the year across different therapeutic areas

  • Industry-Leading Growth: We have consistently delivered above-market growth. Our top 15 brands are market leaders in their respective segments, accounting for over 80% of our revenue. 6 Brands in top 100, 11 Brands in top 300

  • Our advanced manufacturing plant in Goa produces high-quality products, strengthening our relationships with doctors and patients. A significant 20.1% of Net Sales comes from Goa-manufactured items.

  • With a portfolio featuring 125+ products and 10 annual additions, Abbott India addresses diverse health needs while fostering innovation. Revenue: ₹5,349 Crores (8.9% growth) Return on Average Capital Employed: 31.6% Earnings per Share: ₹446.78 PAT (Profit After Tax): ₹949 Crores (18.9% growth) EBITDA : ₹1,360 Crores (16.7% growth)

  • The pandemic prompted Abbott's focus on digital health solutions and patient support. Post-pandemic, Abbott anticipates changes in healthcare behavior, including digitization and a human-centric approach.

  • The expansion of Abbott India's footprint across established and new therapy areas has consistently surpassed industry benchmarks. Noteworthy product launches, such as Udiliv and Thyronorm, highlight Abbott's success.

  • Duphaston in the Women’s Health portfolio, Cremagel-L in gastroenterology, and innovative campaigns across divisions reinforce Abbott's industry leadership.

  • During FY 2023 ,6 Clinical studies were completed and 8 New clinical studies conducted.

  • Abbott joined forces with AmeriCares to elevate 75 Primary Healthcare Centers (PHCs) in 9 states to Health & Wellness Centers (HWCs). The collaborative efforts have yielded tangible results, as reflected in increased footfalls at the HWCs.

  • India, often referred to as the world's pharmacy, has witnessed a significant surge in its pharmaceutical exports, marking a 138% increase. The value has grown from ₹37,987.68 Crores in 2013-14 to ₹90,324.23 Crores in 2021-22. This remarkable growth underscores India's crucial role in global pharmaceutical trade.

  • As per IQVIA, India's domestic pharmaceuticals market (IPM) is estimated to be ₹2,21,922 Crores in 2023, with a 9.5% growth compared to 6.6% in 2022. Branded generics hold an 80% market share by value. Despite regulatory efforts, brand reputation remains vital. The market is projected to grow at an 8.8% CAGR from 2022-2027, reaching ₹3,08,329 Crores, driven by economic growth, health insurance penetration, and private sector investments.



0 comments

Comments


bottom of page